Form 4: Merit Medical Systems CEO Lampropoulos Reports Stock Transactions
SEC Form 4 Filing
CEO Fred Lampropoulos reports acquisition and disposal of Merit Medical Systems Inc. stock, including grants of restricted stock units and performance stock units.
Summary
- Fred P. Lampropoulos, the President and CEO of Merit Medical Systems Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On March 4, 2024, Lampropoulos acquired 24,572 shares of common stock through a grant of restricted stock units (RSUs).
- These RSUs vest in four equal annual installments.
- He also acquired 18,962 shares upon meeting certain conditions for performance stock units granted on March 19, 2021.
- Additionally, 8,343 shares were surrendered to cover tax withholding obligations related to the performance stock units at a price of $76.51.
- Following these transactions, Lampropoulos directly owns 1,067,751 shares of common stock.
- He also indirectly owns shares through his spouse, a 401(k) plan, and as custodian for a child.
- Lampropoulos also holds non-qualified stock options with various exercise prices and expiration dates.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares through RSUs and performance units suggests confidence, but the tax-related sale is a minor negative.
Positives
- The acquisition of shares through RSUs and performance stock units suggests confidence in the company's future performance.
- The vesting schedule of the RSUs incentivizes continued service by the CEO.
Negatives
- The surrender of shares to cover tax obligations, while a normal occurrence, reduces the CEO's overall holdings.
Risks
- The value of the stock options is dependent on the future performance of the company's stock price.
- Changes in tax laws could impact the value of the RSUs and stock options.
Industry Context
Executive stock transactions are common and closely watched as indicators of management's confidence in the company's prospects. Grants of RSUs and performance-based shares are standard compensation practices.
Comparison to Industry Standards
- Executive compensation packages often include a mix of salary, stock options, and restricted stock units.
- The vesting schedules for RSUs and stock options are typical, designed to align executive interests with long-term shareholder value.
- Comparing Lampropoulos's holdings and transactions to those of CEOs at similar-sized medical device companies (e.g., Medtronic, Boston Scientific) could provide further context.
Stakeholder Impact
- The CEO's stock transactions can influence investor sentiment and potentially impact the company's stock price.
- The vesting schedules of RSUs and stock options are designed to align the CEO's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/02/2019 | Date when non-qualified stock options become exercisable in installments. |
| 03/01/2020 | Date when non-qualified stock options become exercisable in installments. |
| 06/22/2020 | Date when unvested options from previous grants were forfeited. |
| 02/26/2021 | Date when non-qualified stock options become exercisable in installments. |
| 03/19/2021 | Date of grant for performance stock units. |
| 03/19/2022 | Date when non-qualified stock options become exercisable in installments. |
| 02/28/2024 | Date when non-qualified stock options become exercisable in installments. |
| 03/04/2024 | Date of the reported transactions, including RSU grant and acquisition of shares from performance stock units. |
| 03/06/2024 | Date of signature for the Form 4 filing. |
| 03/02/2025 | Expiration date for non-qualified stock options. |
| 03/01/2026 | Expiration date for non-qualified stock options. |
| 02/26/2027 | Expiration date for non-qualified stock options. |
| 03/19/2028 | Expiration date for non-qualified stock options. |
| 02/28/2030 | Expiration date for non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.